nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—DPP4—type 2 diabetes mellitus	0.368	1	CbGaD
Vidarabine—DPP4—Linagliptin—type 2 diabetes mellitus	0.241	0.529	CbGbCtD
Vidarabine—DPP4—Sitagliptin—type 2 diabetes mellitus	0.215	0.471	CbGbCtD
Vidarabine—ADA—brown adipose tissue—type 2 diabetes mellitus	0.00706	0.277	CbGeAlD
Vidarabine—ADK—islet of Langerhans—type 2 diabetes mellitus	0.00122	0.0479	CbGeAlD
Vidarabine—DPP4—islet of Langerhans—type 2 diabetes mellitus	0.00118	0.0465	CbGeAlD
Vidarabine—ADA—cardiovascular system—type 2 diabetes mellitus	0.00108	0.0424	CbGeAlD
Vidarabine—ADK—retina—type 2 diabetes mellitus	0.00104	0.041	CbGeAlD
Vidarabine—ADORA2A—cardiovascular system—type 2 diabetes mellitus	0.000984	0.0386	CbGeAlD
Vidarabine—ADK—nephron tubule—type 2 diabetes mellitus	0.000984	0.0386	CbGeAlD
Vidarabine—DPP4—nephron tubule—type 2 diabetes mellitus	0.000954	0.0374	CbGeAlD
Vidarabine—ADA—adipose tissue—type 2 diabetes mellitus	0.000954	0.0374	CbGeAlD
Vidarabine—ADK—cardiovascular system—type 2 diabetes mellitus	0.000884	0.0347	CbGeAlD
Vidarabine—ADK—kidney—type 2 diabetes mellitus	0.000864	0.0339	CbGeAlD
Vidarabine—ADK—pancreas—type 2 diabetes mellitus	0.000859	0.0337	CbGeAlD
Vidarabine—DPP4—cardiovascular system—type 2 diabetes mellitus	0.000857	0.0336	CbGeAlD
Vidarabine—ADK—cortex of kidney—type 2 diabetes mellitus	0.000842	0.033	CbGeAlD
Vidarabine—DPP4—kidney—type 2 diabetes mellitus	0.000838	0.0329	CbGeAlD
Vidarabine—DPP4—pancreas—type 2 diabetes mellitus	0.000833	0.0327	CbGeAlD
Vidarabine—DPP4—cortex of kidney—type 2 diabetes mellitus	0.000816	0.032	CbGeAlD
Vidarabine—ADK—adipose tissue—type 2 diabetes mellitus	0.000779	0.0306	CbGeAlD
Vidarabine—DPP4—adipose tissue—type 2 diabetes mellitus	0.000755	0.0296	CbGeAlD
Vidarabine—S-Adenosylmethionine—MAT1A—type 2 diabetes mellitus	0.000655	0.162	CrCbGaD
Vidarabine—ADORA2A—liver—type 2 diabetes mellitus	0.000608	0.0239	CbGeAlD
Vidarabine—Ribavirin—ENPP1—type 2 diabetes mellitus	0.000604	0.149	CrCbGaD
Vidarabine—ADK—liver—type 2 diabetes mellitus	0.000546	0.0214	CbGeAlD
Vidarabine—DPP4—liver—type 2 diabetes mellitus	0.00053	0.0208	CbGeAlD
Vidarabine—S-Adenosylmethionine—CBS—type 2 diabetes mellitus	0.000422	0.104	CrCbGaD
Vidarabine—Azacitidine—DNMT1—type 2 diabetes mellitus	0.000315	0.0779	CrCbGaD
Vidarabine—Decitabine—DNMT1—type 2 diabetes mellitus	0.000308	0.0761	CrCbGaD
Vidarabine—Adenosine monophosphate—PRKAA1—type 2 diabetes mellitus	0.000268	0.0663	CrCbGaD
Vidarabine—Adenosine triphosphate—PRKAA1—type 2 diabetes mellitus	0.000232	0.0575	CrCbGaD
Vidarabine—Adenosine—DPP4—type 2 diabetes mellitus	0.000213	0.0526	CrCbGaD
Vidarabine—Glucosamine—MMP9—type 2 diabetes mellitus	0.000171	0.0422	CrCbGaD
Vidarabine—Adenosine triphosphate—ABCC8—type 2 diabetes mellitus	0.000137	0.0339	CrCbGaD
Vidarabine—Cardiac disorder—Irbesartan—type 2 diabetes mellitus	0.000124	0.00141	CcSEcCtD
Vidarabine—Discomfort—Gliclazide—type 2 diabetes mellitus	0.000124	0.00141	CcSEcCtD
Vidarabine—Angioedema—Valsartan—type 2 diabetes mellitus	0.000123	0.0014	CcSEcCtD
Vidarabine—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.000122	0.00139	CcSEcCtD
Vidarabine—Dry mouth—Gliclazide—type 2 diabetes mellitus	0.000122	0.00139	CcSEcCtD
Vidarabine—Angioedema—Orlistat—type 2 diabetes mellitus	0.000122	0.00139	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Glyburide—type 2 diabetes mellitus	0.000122	0.00138	CcSEcCtD
Vidarabine—Syncope—Valsartan—type 2 diabetes mellitus	0.000121	0.00138	CcSEcCtD
Vidarabine—Dysgeusia—Metformin—type 2 diabetes mellitus	0.00012	0.00137	CcSEcCtD
Vidarabine—Mediastinal disorder—Irbesartan—type 2 diabetes mellitus	0.00012	0.00137	CcSEcCtD
Vidarabine—Paraesthesia—Glyburide—type 2 diabetes mellitus	0.00012	0.00136	CcSEcCtD
Vidarabine—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.000119	0.00136	CcSEcCtD
Vidarabine—Palpitations—Valsartan—type 2 diabetes mellitus	0.000119	0.00136	CcSEcCtD
Vidarabine—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000119	0.00136	CcSEcCtD
Vidarabine—Dyspnoea—Glyburide—type 2 diabetes mellitus	0.000119	0.00135	CcSEcCtD
Vidarabine—Arrhythmia—Irbesartan—type 2 diabetes mellitus	0.000119	0.00135	CcSEcCtD
Vidarabine—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.000119	0.00135	CcSEcCtD
Vidarabine—Loss of consciousness—Valsartan—type 2 diabetes mellitus	0.000119	0.00135	CcSEcCtD
Vidarabine—Acute coronary syndrome—Ramipril—type 2 diabetes mellitus	0.000118	0.00134	CcSEcCtD
Vidarabine—Palpitations—Orlistat—type 2 diabetes mellitus	0.000118	0.00134	CcSEcCtD
Vidarabine—Cough—Valsartan—type 2 diabetes mellitus	0.000118	0.00134	CcSEcCtD
Vidarabine—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000118	0.00134	CcSEcCtD
Vidarabine—Myocardial infarction—Ramipril—type 2 diabetes mellitus	0.000117	0.00134	CcSEcCtD
Vidarabine—Tachycardia—Gliclazide—type 2 diabetes mellitus	0.000117	0.00133	CcSEcCtD
Vidarabine—Tinnitus—Losartan—type 2 diabetes mellitus	0.000117	0.00133	CcSEcCtD
Vidarabine—Cough—Orlistat—type 2 diabetes mellitus	0.000116	0.00132	CcSEcCtD
Vidarabine—Flushing—Losartan—type 2 diabetes mellitus	0.000116	0.00132	CcSEcCtD
Vidarabine—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000116	0.00132	CcSEcCtD
Vidarabine—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.000116	0.00132	CcSEcCtD
Vidarabine—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	0.000116	0.00132	CcSEcCtD
Vidarabine—Vision blurred—Metformin—type 2 diabetes mellitus	0.000116	0.00132	CcSEcCtD
Vidarabine—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000116	0.00132	CcSEcCtD
Vidarabine—Convulsion—Orlistat—type 2 diabetes mellitus	0.000116	0.00131	CcSEcCtD
Vidarabine—Tremor—Metformin—type 2 diabetes mellitus	0.000115	0.00131	CcSEcCtD
Vidarabine—Chest pain—Valsartan—type 2 diabetes mellitus	0.000115	0.00131	CcSEcCtD
Vidarabine—Sweating—Ramipril—type 2 diabetes mellitus	0.000115	0.00131	CcSEcCtD
Vidarabine—Dizziness—Glipizide—type 2 diabetes mellitus	0.000115	0.00131	CcSEcCtD
Vidarabine—Anxiety—Valsartan—type 2 diabetes mellitus	0.000114	0.0013	CcSEcCtD
Vidarabine—Tension—Irbesartan—type 2 diabetes mellitus	0.000114	0.0013	CcSEcCtD
Vidarabine—Dysgeusia—Irbesartan—type 2 diabetes mellitus	0.000114	0.00129	CcSEcCtD
Vidarabine—Chest pain—Orlistat—type 2 diabetes mellitus	0.000114	0.00129	CcSEcCtD
Vidarabine—Anxiety—Orlistat—type 2 diabetes mellitus	0.000113	0.00129	CcSEcCtD
Vidarabine—Nervousness—Irbesartan—type 2 diabetes mellitus	0.000113	0.00128	CcSEcCtD
Vidarabine—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000112	0.00128	CcSEcCtD
Vidarabine—Glucosamine—TNF—type 2 diabetes mellitus	0.000112	0.0278	CrCbGaD
Vidarabine—Discomfort—Orlistat—type 2 diabetes mellitus	0.000112	0.00128	CcSEcCtD
Vidarabine—Hypotension—Gliclazide—type 2 diabetes mellitus	0.000112	0.00127	CcSEcCtD
Vidarabine—Arrhythmia—Losartan—type 2 diabetes mellitus	0.000112	0.00127	CcSEcCtD
Vidarabine—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000111	0.00126	CcSEcCtD
Vidarabine—Vomiting—Glipizide—type 2 diabetes mellitus	0.00011	0.00126	CcSEcCtD
Vidarabine—Syncope—Metformin—type 2 diabetes mellitus	0.00011	0.00125	CcSEcCtD
Vidarabine—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.00011	0.00125	CcSEcCtD
Vidarabine—Adenosine triphosphate—AKT1—type 2 diabetes mellitus	0.00011	0.0272	CrCbGaD
Vidarabine—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.00011	0.00125	CcSEcCtD
Vidarabine—Rash—Glipizide—type 2 diabetes mellitus	0.000109	0.00124	CcSEcCtD
Vidarabine—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000109	0.00124	CcSEcCtD
Vidarabine—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000109	0.00124	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.000109	0.00124	CcSEcCtD
Vidarabine—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.000109	0.00124	CcSEcCtD
Vidarabine—Headache—Glipizide—type 2 diabetes mellitus	0.000109	0.00124	CcSEcCtD
Vidarabine—Tremor—Irbesartan—type 2 diabetes mellitus	0.000109	0.00124	CcSEcCtD
Vidarabine—Palpitations—Metformin—type 2 diabetes mellitus	0.000109	0.00124	CcSEcCtD
Vidarabine—Shock—Valsartan—type 2 diabetes mellitus	0.000108	0.00123	CcSEcCtD
Vidarabine—Adenosine monophosphate—SRC—type 2 diabetes mellitus	0.000108	0.0268	CrCbGaD
Vidarabine—Loss of consciousness—Metformin—type 2 diabetes mellitus	0.000108	0.00123	CcSEcCtD
Vidarabine—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.000108	0.00123	CcSEcCtD
Vidarabine—Tension—Losartan—type 2 diabetes mellitus	0.000107	0.00122	CcSEcCtD
Vidarabine—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000107	0.00122	CcSEcCtD
Vidarabine—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000107	0.00122	CcSEcCtD
Vidarabine—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000107	0.00122	CcSEcCtD
Vidarabine—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000107	0.00121	CcSEcCtD
Vidarabine—Agitation—Irbesartan—type 2 diabetes mellitus	0.000107	0.00121	CcSEcCtD
Vidarabine—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000107	0.00121	CcSEcCtD
Vidarabine—Hypertension—Metformin—type 2 diabetes mellitus	0.000106	0.00121	CcSEcCtD
Vidarabine—Urticaria—Glyburide—type 2 diabetes mellitus	0.000106	0.00121	CcSEcCtD
Vidarabine—Nervousness—Losartan—type 2 diabetes mellitus	0.000106	0.00121	CcSEcCtD
Vidarabine—Angioedema—Irbesartan—type 2 diabetes mellitus	0.000106	0.00121	CcSEcCtD
Vidarabine—Back pain—Losartan—type 2 diabetes mellitus	0.000106	0.0012	CcSEcCtD
Vidarabine—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	0.000105	0.0012	CcSEcCtD
Vidarabine—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000105	0.00119	CcSEcCtD
Vidarabine—Chest pain—Metformin—type 2 diabetes mellitus	0.000105	0.00119	CcSEcCtD
Vidarabine—Headache—Pioglitazone—type 2 diabetes mellitus	0.000104	0.00118	CcSEcCtD
Vidarabine—Syncope—Irbesartan—type 2 diabetes mellitus	0.000104	0.00118	CcSEcCtD
Vidarabine—Discomfort—Metformin—type 2 diabetes mellitus	0.000103	0.00118	CcSEcCtD
Vidarabine—Nausea—Glipizide—type 2 diabetes mellitus	0.000103	0.00117	CcSEcCtD
Vidarabine—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000103	0.00117	CcSEcCtD
Vidarabine—Hypotension—Valsartan—type 2 diabetes mellitus	0.000103	0.00117	CcSEcCtD
Vidarabine—Vision blurred—Losartan—type 2 diabetes mellitus	0.000103	0.00117	CcSEcCtD
Vidarabine—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000103	0.00117	CcSEcCtD
Vidarabine—Pain—Gliclazide—type 2 diabetes mellitus	0.000103	0.00117	CcSEcCtD
Vidarabine—Tremor—Losartan—type 2 diabetes mellitus	0.000102	0.00116	CcSEcCtD
Vidarabine—Rash—Glimepiride—type 2 diabetes mellitus	0.000102	0.00116	CcSEcCtD
Vidarabine—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000102	0.00116	CcSEcCtD
Vidarabine—Loss of consciousness—Irbesartan—type 2 diabetes mellitus	0.000102	0.00116	CcSEcCtD
Vidarabine—Rash—Sitagliptin—type 2 diabetes mellitus	0.000102	0.00116	CcSEcCtD
Vidarabine—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000102	0.00116	CcSEcCtD
Vidarabine—Headache—Glimepiride—type 2 diabetes mellitus	0.000101	0.00115	CcSEcCtD
Vidarabine—Cough—Irbesartan—type 2 diabetes mellitus	0.000101	0.00115	CcSEcCtD
Vidarabine—Headache—Sitagliptin—type 2 diabetes mellitus	0.000101	0.00115	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.0001	0.00114	CcSEcCtD
Vidarabine—Agitation—Losartan—type 2 diabetes mellitus	0.0001	0.00114	CcSEcCtD
Vidarabine—Tinnitus—Ramipril—type 2 diabetes mellitus	0.0001	0.00114	CcSEcCtD
Vidarabine—Hypertension—Irbesartan—type 2 diabetes mellitus	0.0001	0.00114	CcSEcCtD
Vidarabine—Flushing—Ramipril—type 2 diabetes mellitus	9.98e-05	0.00114	CcSEcCtD
Vidarabine—Angioedema—Losartan—type 2 diabetes mellitus	9.97e-05	0.00114	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	9.91e-05	0.00113	CcSEcCtD
Vidarabine—Paraesthesia—Valsartan—type 2 diabetes mellitus	9.89e-05	0.00113	CcSEcCtD
Vidarabine—Chest pain—Irbesartan—type 2 diabetes mellitus	9.87e-05	0.00112	CcSEcCtD
Vidarabine—Shock—Metformin—type 2 diabetes mellitus	9.87e-05	0.00112	CcSEcCtD
Vidarabine—Anxiety—Irbesartan—type 2 diabetes mellitus	9.84e-05	0.00112	CcSEcCtD
Vidarabine—Hypersensitivity—Glyburide—type 2 diabetes mellitus	9.84e-05	0.00112	CcSEcCtD
Vidarabine—Dyspnoea—Valsartan—type 2 diabetes mellitus	9.82e-05	0.00112	CcSEcCtD
Vidarabine—Somnolence—Valsartan—type 2 diabetes mellitus	9.79e-05	0.00111	CcSEcCtD
Vidarabine—Syncope—Losartan—type 2 diabetes mellitus	9.79e-05	0.00111	CcSEcCtD
Vidarabine—Paraesthesia—Orlistat—type 2 diabetes mellitus	9.77e-05	0.00111	CcSEcCtD
Vidarabine—Discomfort—Irbesartan—type 2 diabetes mellitus	9.75e-05	0.00111	CcSEcCtD
Vidarabine—Hyperhidrosis—Metformin—type 2 diabetes mellitus	9.7e-05	0.0011	CcSEcCtD
Vidarabine—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	9.69e-05	0.0011	CcSEcCtD
Vidarabine—Tenofovir—ABCC2—type 2 diabetes mellitus	9.67e-05	0.0239	CrCbGaD
Vidarabine—Dizziness—Bromocriptine—type 2 diabetes mellitus	9.66e-05	0.0011	CcSEcCtD
Vidarabine—Dry mouth—Irbesartan—type 2 diabetes mellitus	9.66e-05	0.0011	CcSEcCtD
Vidarabine—Palpitations—Losartan—type 2 diabetes mellitus	9.64e-05	0.0011	CcSEcCtD
Vidarabine—Nausea—Glimepiride—type 2 diabetes mellitus	9.61e-05	0.00109	CcSEcCtD
Vidarabine—Arrhythmia—Ramipril—type 2 diabetes mellitus	9.6e-05	0.00109	CcSEcCtD
Vidarabine—Loss of consciousness—Losartan—type 2 diabetes mellitus	9.59e-05	0.00109	CcSEcCtD
Vidarabine—Nausea—Sitagliptin—type 2 diabetes mellitus	9.58e-05	0.00109	CcSEcCtD
Vidarabine—Asthenia—Glyburide—type 2 diabetes mellitus	9.58e-05	0.00109	CcSEcCtD
Vidarabine—Cough—Losartan—type 2 diabetes mellitus	9.52e-05	0.00108	CcSEcCtD
Vidarabine—Urticaria—Gliclazide—type 2 diabetes mellitus	9.52e-05	0.00108	CcSEcCtD
Vidarabine—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	9.46e-05	0.00108	CcSEcCtD
Vidarabine—Hypotension—Metformin—type 2 diabetes mellitus	9.37e-05	0.00107	CcSEcCtD
Vidarabine—Shock—Irbesartan—type 2 diabetes mellitus	9.31e-05	0.00106	CcSEcCtD
Vidarabine—Pain—Orlistat—type 2 diabetes mellitus	9.31e-05	0.00106	CcSEcCtD
Vidarabine—Chest pain—Losartan—type 2 diabetes mellitus	9.29e-05	0.00106	CcSEcCtD
Vidarabine—Vomiting—Bromocriptine—type 2 diabetes mellitus	9.28e-05	0.00106	CcSEcCtD
Vidarabine—Anxiety—Losartan—type 2 diabetes mellitus	9.26e-05	0.00105	CcSEcCtD
Vidarabine—Tachycardia—Irbesartan—type 2 diabetes mellitus	9.24e-05	0.00105	CcSEcCtD
Vidarabine—Rash—Bromocriptine—type 2 diabetes mellitus	9.21e-05	0.00105	CcSEcCtD
Vidarabine—Dermatitis—Bromocriptine—type 2 diabetes mellitus	9.2e-05	0.00105	CcSEcCtD
Vidarabine—Tension—Ramipril—type 2 diabetes mellitus	9.18e-05	0.00105	CcSEcCtD
Vidarabine—Discomfort—Losartan—type 2 diabetes mellitus	9.18e-05	0.00104	CcSEcCtD
Vidarabine—Dysgeusia—Ramipril—type 2 diabetes mellitus	9.16e-05	0.00104	CcSEcCtD
Vidarabine—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	9.15e-05	0.00104	CcSEcCtD
Vidarabine—Headache—Bromocriptine—type 2 diabetes mellitus	9.15e-05	0.00104	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	9.14e-05	0.00104	CcSEcCtD
Vidarabine—Nervousness—Ramipril—type 2 diabetes mellitus	9.09e-05	0.00103	CcSEcCtD
Vidarabine—Dry mouth—Losartan—type 2 diabetes mellitus	9.09e-05	0.00103	CcSEcCtD
Vidarabine—Paraesthesia—Metformin—type 2 diabetes mellitus	9.01e-05	0.00102	CcSEcCtD
Vidarabine—Dyspnoea—Metformin—type 2 diabetes mellitus	8.94e-05	0.00102	CcSEcCtD
Vidarabine—Somnolence—Metformin—type 2 diabetes mellitus	8.92e-05	0.00101	CcSEcCtD
Vidarabine—Anaphylactic shock—Losartan—type 2 diabetes mellitus	8.91e-05	0.00101	CcSEcCtD
Vidarabine—Hypotension—Irbesartan—type 2 diabetes mellitus	8.84e-05	0.00101	CcSEcCtD
Vidarabine—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	8.83e-05	0.00101	CcSEcCtD
Vidarabine—Tremor—Ramipril—type 2 diabetes mellitus	8.77e-05	0.000998	CcSEcCtD
Vidarabine—Shock—Losartan—type 2 diabetes mellitus	8.76e-05	0.000997	CcSEcCtD
Vidarabine—Urticaria—Valsartan—type 2 diabetes mellitus	8.75e-05	0.000996	CcSEcCtD
Vidarabine—Tachycardia—Losartan—type 2 diabetes mellitus	8.69e-05	0.000989	CcSEcCtD
Vidarabine—Nausea—Bromocriptine—type 2 diabetes mellitus	8.67e-05	0.000987	CcSEcCtD
Vidarabine—Glucosamine—CYP2E1—type 2 diabetes mellitus	8.65e-05	0.0214	CrCbGaD
Vidarabine—Urticaria—Orlistat—type 2 diabetes mellitus	8.65e-05	0.000984	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	8.62e-05	0.000981	CcSEcCtD
Vidarabine—Hyperhidrosis—Losartan—type 2 diabetes mellitus	8.61e-05	0.00098	CcSEcCtD
Vidarabine—Asthenia—Gliclazide—type 2 diabetes mellitus	8.6e-05	0.000979	CcSEcCtD
Vidarabine—Agitation—Ramipril—type 2 diabetes mellitus	8.6e-05	0.000979	CcSEcCtD
Vidarabine—Angioedema—Ramipril—type 2 diabetes mellitus	8.55e-05	0.000973	CcSEcCtD
Vidarabine—Paraesthesia—Irbesartan—type 2 diabetes mellitus	8.5e-05	0.000967	CcSEcCtD
Vidarabine—Vomiting—Glyburide—type 2 diabetes mellitus	8.49e-05	0.000966	CcSEcCtD
Vidarabine—Dyspnoea—Irbesartan—type 2 diabetes mellitus	8.44e-05	0.00096	CcSEcCtD
Vidarabine—Rash—Glyburide—type 2 diabetes mellitus	8.42e-05	0.000958	CcSEcCtD
Vidarabine—Somnolence—Irbesartan—type 2 diabetes mellitus	8.41e-05	0.000958	CcSEcCtD
Vidarabine—Dermatitis—Glyburide—type 2 diabetes mellitus	8.41e-05	0.000957	CcSEcCtD
Vidarabine—Syncope—Ramipril—type 2 diabetes mellitus	8.39e-05	0.000955	CcSEcCtD
Vidarabine—Headache—Glyburide—type 2 diabetes mellitus	8.36e-05	0.000952	CcSEcCtD
Vidarabine—Hypotension—Losartan—type 2 diabetes mellitus	8.32e-05	0.000947	CcSEcCtD
Vidarabine—Palpitations—Ramipril—type 2 diabetes mellitus	8.27e-05	0.000941	CcSEcCtD
Vidarabine—Loss of consciousness—Ramipril—type 2 diabetes mellitus	8.22e-05	0.000936	CcSEcCtD
Vidarabine—Cough—Ramipril—type 2 diabetes mellitus	8.17e-05	0.000929	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	8.11e-05	0.000924	CcSEcCtD
Vidarabine—Hypersensitivity—Valsartan—type 2 diabetes mellitus	8.11e-05	0.000924	CcSEcCtD
Vidarabine—Convulsion—Ramipril—type 2 diabetes mellitus	8.11e-05	0.000923	CcSEcCtD
Vidarabine—Pain—Irbesartan—type 2 diabetes mellitus	8.09e-05	0.000921	CcSEcCtD
Vidarabine—Hypersensitivity—Orlistat—type 2 diabetes mellitus	8.02e-05	0.000913	CcSEcCtD
Vidarabine—Paraesthesia—Losartan—type 2 diabetes mellitus	8e-05	0.00091	CcSEcCtD
Vidarabine—Urticaria—Metformin—type 2 diabetes mellitus	7.97e-05	0.000907	CcSEcCtD
Vidarabine—Chest pain—Ramipril—type 2 diabetes mellitus	7.97e-05	0.000907	CcSEcCtD
Vidarabine—Dyspnoea—Losartan—type 2 diabetes mellitus	7.94e-05	0.000904	CcSEcCtD
Vidarabine—Anxiety—Ramipril—type 2 diabetes mellitus	7.94e-05	0.000904	CcSEcCtD
Vidarabine—Nausea—Glyburide—type 2 diabetes mellitus	7.93e-05	0.000903	CcSEcCtD
Vidarabine—Dizziness—Gliclazide—type 2 diabetes mellitus	7.93e-05	0.000902	CcSEcCtD
Vidarabine—Somnolence—Losartan—type 2 diabetes mellitus	7.92e-05	0.000901	CcSEcCtD
Vidarabine—Asthenia—Valsartan—type 2 diabetes mellitus	7.9e-05	0.000899	CcSEcCtD
Vidarabine—Discomfort—Ramipril—type 2 diabetes mellitus	7.87e-05	0.000896	CcSEcCtD
Vidarabine—Asthenia—Orlistat—type 2 diabetes mellitus	7.81e-05	0.000889	CcSEcCtD
Vidarabine—Dry mouth—Ramipril—type 2 diabetes mellitus	7.79e-05	0.000887	CcSEcCtD
Vidarabine—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	7.64e-05	0.000869	CcSEcCtD
Vidarabine—Vomiting—Gliclazide—type 2 diabetes mellitus	7.62e-05	0.000867	CcSEcCtD
Vidarabine—Pain—Losartan—type 2 diabetes mellitus	7.62e-05	0.000867	CcSEcCtD
Vidarabine—Rash—Gliclazide—type 2 diabetes mellitus	7.56e-05	0.00086	CcSEcCtD
Vidarabine—Dermatitis—Gliclazide—type 2 diabetes mellitus	7.55e-05	0.000859	CcSEcCtD
Vidarabine—Urticaria—Irbesartan—type 2 diabetes mellitus	7.52e-05	0.000856	CcSEcCtD
Vidarabine—Shock—Ramipril—type 2 diabetes mellitus	7.51e-05	0.000855	CcSEcCtD
Vidarabine—Headache—Gliclazide—type 2 diabetes mellitus	7.51e-05	0.000855	CcSEcCtD
Vidarabine—Tachycardia—Ramipril—type 2 diabetes mellitus	7.45e-05	0.000848	CcSEcCtD
Vidarabine—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	7.38e-05	0.00084	CcSEcCtD
Vidarabine—Dizziness—Valsartan—type 2 diabetes mellitus	7.28e-05	0.000829	CcSEcCtD
Vidarabine—Dizziness—Orlistat—type 2 diabetes mellitus	7.2e-05	0.000819	CcSEcCtD
Vidarabine—Asthenia—Metformin—type 2 diabetes mellitus	7.2e-05	0.000819	CcSEcCtD
Vidarabine—Hypotension—Ramipril—type 2 diabetes mellitus	7.14e-05	0.000812	CcSEcCtD
Vidarabine—Nausea—Gliclazide—type 2 diabetes mellitus	7.12e-05	0.00081	CcSEcCtD
Vidarabine—Urticaria—Losartan—type 2 diabetes mellitus	7.08e-05	0.000805	CcSEcCtD
Vidarabine—Vomiting—Valsartan—type 2 diabetes mellitus	7e-05	0.000797	CcSEcCtD
Vidarabine—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	6.97e-05	0.000794	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	6.96e-05	0.000792	CcSEcCtD
Vidarabine—Rash—Valsartan—type 2 diabetes mellitus	6.94e-05	0.00079	CcSEcCtD
Vidarabine—Dermatitis—Valsartan—type 2 diabetes mellitus	6.94e-05	0.00079	CcSEcCtD
Vidarabine—Vomiting—Orlistat—type 2 diabetes mellitus	6.92e-05	0.000788	CcSEcCtD
Vidarabine—Headache—Valsartan—type 2 diabetes mellitus	6.9e-05	0.000785	CcSEcCtD
Vidarabine—Rash—Orlistat—type 2 diabetes mellitus	6.86e-05	0.000781	CcSEcCtD
Vidarabine—Paraesthesia—Ramipril—type 2 diabetes mellitus	6.86e-05	0.000781	CcSEcCtD
Vidarabine—Dermatitis—Orlistat—type 2 diabetes mellitus	6.86e-05	0.00078	CcSEcCtD
Vidarabine—Headache—Orlistat—type 2 diabetes mellitus	6.82e-05	0.000776	CcSEcCtD
Vidarabine—Dyspnoea—Ramipril—type 2 diabetes mellitus	6.81e-05	0.000775	CcSEcCtD
Vidarabine—Asthenia—Irbesartan—type 2 diabetes mellitus	6.79e-05	0.000773	CcSEcCtD
Vidarabine—Somnolence—Ramipril—type 2 diabetes mellitus	6.79e-05	0.000773	CcSEcCtD
Vidarabine—Dizziness—Metformin—type 2 diabetes mellitus	6.63e-05	0.000755	CcSEcCtD
Vidarabine—Hypersensitivity—Losartan—type 2 diabetes mellitus	6.56e-05	0.000747	CcSEcCtD
Vidarabine—Nausea—Valsartan—type 2 diabetes mellitus	6.54e-05	0.000745	CcSEcCtD
Vidarabine—Nausea—Orlistat—type 2 diabetes mellitus	6.46e-05	0.000736	CcSEcCtD
Vidarabine—Tenofovir—CYP1A2—type 2 diabetes mellitus	6.45e-05	0.016	CrCbGaD
Vidarabine—Asthenia—Losartan—type 2 diabetes mellitus	6.39e-05	0.000727	CcSEcCtD
Vidarabine—Vomiting—Metformin—type 2 diabetes mellitus	6.38e-05	0.000726	CcSEcCtD
Vidarabine—Rash—Metformin—type 2 diabetes mellitus	6.32e-05	0.00072	CcSEcCtD
Vidarabine—Dermatitis—Metformin—type 2 diabetes mellitus	6.32e-05	0.000719	CcSEcCtD
Vidarabine—Headache—Metformin—type 2 diabetes mellitus	6.28e-05	0.000715	CcSEcCtD
Vidarabine—Dizziness—Irbesartan—type 2 diabetes mellitus	6.26e-05	0.000712	CcSEcCtD
Vidarabine—Urticaria—Ramipril—type 2 diabetes mellitus	6.07e-05	0.000691	CcSEcCtD
Vidarabine—Vomiting—Irbesartan—type 2 diabetes mellitus	6.02e-05	0.000685	CcSEcCtD
Vidarabine—Rash—Irbesartan—type 2 diabetes mellitus	5.97e-05	0.000679	CcSEcCtD
Vidarabine—Dermatitis—Irbesartan—type 2 diabetes mellitus	5.96e-05	0.000679	CcSEcCtD
Vidarabine—Nausea—Metformin—type 2 diabetes mellitus	5.96e-05	0.000678	CcSEcCtD
Vidarabine—Headache—Irbesartan—type 2 diabetes mellitus	5.93e-05	0.000675	CcSEcCtD
Vidarabine—S-Adenosylmethionine—CYP2E1—type 2 diabetes mellitus	5.93e-05	0.0147	CrCbGaD
Vidarabine—Dizziness—Losartan—type 2 diabetes mellitus	5.89e-05	0.00067	CcSEcCtD
Vidarabine—Vomiting—Losartan—type 2 diabetes mellitus	5.66e-05	0.000645	CcSEcCtD
Vidarabine—Hypersensitivity—Ramipril—type 2 diabetes mellitus	5.63e-05	0.00064	CcSEcCtD
Vidarabine—Nausea—Irbesartan—type 2 diabetes mellitus	5.62e-05	0.00064	CcSEcCtD
Vidarabine—Rash—Losartan—type 2 diabetes mellitus	5.62e-05	0.000639	CcSEcCtD
Vidarabine—Dermatitis—Losartan—type 2 diabetes mellitus	5.61e-05	0.000639	CcSEcCtD
Vidarabine—Headache—Losartan—type 2 diabetes mellitus	5.58e-05	0.000635	CcSEcCtD
Vidarabine—Asthenia—Ramipril—type 2 diabetes mellitus	5.48e-05	0.000624	CcSEcCtD
Vidarabine—Nausea—Losartan—type 2 diabetes mellitus	5.29e-05	0.000602	CcSEcCtD
Vidarabine—Adenosine triphosphate—ABCC2—type 2 diabetes mellitus	5.22e-05	0.0129	CrCbGaD
Vidarabine—Dizziness—Ramipril—type 2 diabetes mellitus	5.05e-05	0.000575	CcSEcCtD
Vidarabine—Vomiting—Ramipril—type 2 diabetes mellitus	4.86e-05	0.000553	CcSEcCtD
Vidarabine—Rash—Ramipril—type 2 diabetes mellitus	4.82e-05	0.000548	CcSEcCtD
Vidarabine—Dermatitis—Ramipril—type 2 diabetes mellitus	4.81e-05	0.000548	CcSEcCtD
Vidarabine—Headache—Ramipril—type 2 diabetes mellitus	4.78e-05	0.000545	CcSEcCtD
Vidarabine—Nausea—Ramipril—type 2 diabetes mellitus	4.54e-05	0.000516	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—AGT—type 2 diabetes mellitus	3.56e-05	0.000607	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP2E1—type 2 diabetes mellitus	3.53e-05	0.000603	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ALDOB—type 2 diabetes mellitus	3.53e-05	0.000603	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP1A2—type 2 diabetes mellitus	3.49e-05	0.000596	CbGpPWpGaD
Vidarabine—ADK—Metabolism—SLC2A1—type 2 diabetes mellitus	3.49e-05	0.000596	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—LEP—type 2 diabetes mellitus	3.49e-05	0.000594	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—SERPINE1—type 2 diabetes mellitus	3.48e-05	0.000594	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCR5—type 2 diabetes mellitus	3.42e-05	0.000584	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IRS2—type 2 diabetes mellitus	3.42e-05	0.000584	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ADRB3—type 2 diabetes mellitus	3.42e-05	0.000583	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP3A4—type 2 diabetes mellitus	3.41e-05	0.000581	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CALM1—type 2 diabetes mellitus	3.36e-05	0.000573	CbGpPWpGaD
Vidarabine—ADK—Metabolism—SLC2A4—type 2 diabetes mellitus	3.35e-05	0.000571	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GCG—type 2 diabetes mellitus	3.35e-05	0.000571	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—C3—type 2 diabetes mellitus	3.35e-05	0.000571	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CRHR1—type 2 diabetes mellitus	3.3e-05	0.000563	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GLP1R—type 2 diabetes mellitus	3.29e-05	0.00056	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3R1—type 2 diabetes mellitus	3.26e-05	0.000556	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—AGT—type 2 diabetes mellitus	3.18e-05	0.000542	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—GNB3—type 2 diabetes mellitus	3.11e-05	0.00053	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ADRB3—type 2 diabetes mellitus	3.1e-05	0.000529	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MTNR1A—type 2 diabetes mellitus	3.08e-05	0.000526	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—AVP—type 2 diabetes mellitus	3.07e-05	0.000523	CbGpPWpGaD
Vidarabine—ADA—Metabolism—SLC2A2—type 2 diabetes mellitus	3.07e-05	0.000523	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—MTNR1B—type 2 diabetes mellitus	3.02e-05	0.000515	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CPT1A—type 2 diabetes mellitus	3e-05	0.000512	CbGpPWpGaD
Vidarabine—ADA—Metabolism—MTR—type 2 diabetes mellitus	3e-05	0.000512	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CRHR1—type 2 diabetes mellitus	3e-05	0.000511	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IRS1—type 2 diabetes mellitus	2.99e-05	0.00051	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—INS—type 2 diabetes mellitus	2.98e-05	0.000508	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NAMPT—type 2 diabetes mellitus	2.95e-05	0.000503	CbGpPWpGaD
Vidarabine—Cytarabine—CYP3A4—type 2 diabetes mellitus	2.95e-05	0.00729	CrCbGaD
Vidarabine—ADORA2A—GPCR downstream signaling—GLP1R—type 2 diabetes mellitus	2.94e-05	0.000502	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CCL2—type 2 diabetes mellitus	2.93e-05	0.0005	CbGpPWpGaD
Vidarabine—ADA—Metabolism—HBA1—type 2 diabetes mellitus	2.93e-05	0.000499	CbGpPWpGaD
Vidarabine—ADA—Metabolism—LIPC—type 2 diabetes mellitus	2.93e-05	0.000499	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GCK—type 2 diabetes mellitus	2.93e-05	0.000499	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—EDN1—type 2 diabetes mellitus	2.92e-05	0.000498	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP11A1—type 2 diabetes mellitus	2.91e-05	0.000496	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CCKAR—type 2 diabetes mellitus	2.89e-05	0.000493	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PPARGC1A—type 2 diabetes mellitus	2.89e-05	0.000492	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GNB3—type 2 diabetes mellitus	2.89e-05	0.000492	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—IL6—type 2 diabetes mellitus	2.89e-05	0.000492	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—IGF1—type 2 diabetes mellitus	2.88e-05	0.000491	CbGpPWpGaD
Vidarabine—ADK—Metabolism—HMOX1—type 2 diabetes mellitus	2.87e-05	0.00049	CbGpPWpGaD
Vidarabine—ADA—Metabolism—SLC9A1—type 2 diabetes mellitus	2.86e-05	0.000487	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CAT—type 2 diabetes mellitus	2.84e-05	0.000484	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CETP—type 2 diabetes mellitus	2.83e-05	0.000482	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—AKT2—type 2 diabetes mellitus	2.77e-05	0.000472	CbGpPWpGaD
Vidarabine—ADK—Metabolism—APOB—type 2 diabetes mellitus	2.75e-05	0.00047	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—MTNR1B—type 2 diabetes mellitus	2.74e-05	0.000467	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GSTM1—type 2 diabetes mellitus	2.68e-05	0.000457	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—GLP1R—type 2 diabetes mellitus	2.67e-05	0.000455	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GCGR—type 2 diabetes mellitus	2.66e-05	0.000454	CbGpPWpGaD
Vidarabine—ADK—Metabolism—LPL—type 2 diabetes mellitus	2.63e-05	0.000448	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CCKAR—type 2 diabetes mellitus	2.63e-05	0.000448	CbGpPWpGaD
Vidarabine—ADA—Metabolism—SNAP25—type 2 diabetes mellitus	2.63e-05	0.000448	CbGpPWpGaD
Vidarabine—ADA—Metabolism—SREBF1—type 2 diabetes mellitus	2.63e-05	0.000448	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PSMD6—type 2 diabetes mellitus	2.63e-05	0.000448	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—type 2 diabetes mellitus	2.62e-05	0.000447	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CCR5—type 2 diabetes mellitus	2.61e-05	0.000445	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—IAPP—type 2 diabetes mellitus	2.61e-05	0.000444	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CTGF—type 2 diabetes mellitus	2.58e-05	0.00044	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ADCY5—type 2 diabetes mellitus	2.57e-05	0.000439	CbGpPWpGaD
Vidarabine—ADK—Metabolism—GPX1—type 2 diabetes mellitus	2.56e-05	0.000437	CbGpPWpGaD
Vidarabine—ADA—Metabolism—HMGCR—type 2 diabetes mellitus	2.55e-05	0.000436	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—C3—type 2 diabetes mellitus	2.55e-05	0.000435	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—TRPC6—type 2 diabetes mellitus	2.54e-05	0.000434	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AGTR2—type 2 diabetes mellitus	2.53e-05	0.000431	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3R1—type 2 diabetes mellitus	2.51e-05	0.000428	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ADRA2A—type 2 diabetes mellitus	2.5e-05	0.000426	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CD36—type 2 diabetes mellitus	2.5e-05	0.000426	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PPP2CA—type 2 diabetes mellitus	2.47e-05	0.000421	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GIPR—type 2 diabetes mellitus	2.45e-05	0.000418	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GRK5—type 2 diabetes mellitus	2.45e-05	0.000418	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—EDNRB—type 2 diabetes mellitus	2.42e-05	0.000413	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—AGT—type 2 diabetes mellitus	2.42e-05	0.000413	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—SRC—type 2 diabetes mellitus	2.41e-05	0.000412	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP2E1—type 2 diabetes mellitus	2.4e-05	0.00041	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP1A2—type 2 diabetes mellitus	2.38e-05	0.000405	CbGpPWpGaD
Vidarabine—ADA—Metabolism—SLC2A1—type 2 diabetes mellitus	2.38e-05	0.000405	CbGpPWpGaD
Vidarabine—ADK—Metabolism—MTHFR—type 2 diabetes mellitus	2.37e-05	0.000404	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IAPP—type 2 diabetes mellitus	2.37e-05	0.000403	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—RELA—type 2 diabetes mellitus	2.36e-05	0.000403	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—HTR2C—type 2 diabetes mellitus	2.35e-05	0.000401	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PPARA—type 2 diabetes mellitus	2.32e-05	0.000396	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP3A4—type 2 diabetes mellitus	2.32e-05	0.000395	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—TRPC6—type 2 diabetes mellitus	2.31e-05	0.000394	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AGTR2—type 2 diabetes mellitus	2.3e-05	0.000392	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—EDNRA—type 2 diabetes mellitus	2.29e-05	0.00039	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GCG—type 2 diabetes mellitus	2.28e-05	0.000388	CbGpPWpGaD
Vidarabine—ADA—Metabolism—SLC2A4—type 2 diabetes mellitus	2.28e-05	0.000388	CbGpPWpGaD
Vidarabine—ADK—Metabolism—AGT—type 2 diabetes mellitus	2.25e-05	0.000384	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MC4R—type 2 diabetes mellitus	2.24e-05	0.000382	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ADRA2A—type 2 diabetes mellitus	2.24e-05	0.000382	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—GHRL—type 2 diabetes mellitus	2.23e-05	0.00038	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CALM1—type 2 diabetes mellitus	2.21e-05	0.000377	CbGpPWpGaD
Vidarabine—ADK—Metabolism—APOE—type 2 diabetes mellitus	2.2e-05	0.000376	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CALCA—type 2 diabetes mellitus	2.2e-05	0.000375	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EDNRB—type 2 diabetes mellitus	2.2e-05	0.000375	CbGpPWpGaD
Vidarabine—ADK—Metabolism—APOA1—type 2 diabetes mellitus	2.18e-05	0.000371	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GIP—type 2 diabetes mellitus	2.16e-05	0.000368	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—HTR2C—type 2 diabetes mellitus	2.14e-05	0.000364	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CASP3—type 2 diabetes mellitus	2.13e-05	0.000363	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—EGFR—type 2 diabetes mellitus	2.12e-05	0.000361	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EDNRA—type 2 diabetes mellitus	2.08e-05	0.000354	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LEPR—type 2 diabetes mellitus	2.05e-05	0.000349	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—GCG—type 2 diabetes mellitus	2.04e-05	0.000348	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ADRA2A—type 2 diabetes mellitus	2.03e-05	0.000347	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—GHRL—type 2 diabetes mellitus	2.02e-05	0.000345	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—RASGRP1—type 2 diabetes mellitus	2.01e-05	0.000342	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CALCA—type 2 diabetes mellitus	2e-05	0.000341	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CCL2—type 2 diabetes mellitus	1.99e-05	0.00034	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—NFKB1—type 2 diabetes mellitus	1.99e-05	0.00034	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.96e-05	0.000335	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GNB3—type 2 diabetes mellitus	1.96e-05	0.000335	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ATP2A3—type 2 diabetes mellitus	1.96e-05	0.000334	CbGpPWpGaD
Vidarabine—ADA—Metabolism—HMOX1—type 2 diabetes mellitus	1.95e-05	0.000333	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CAT—type 2 diabetes mellitus	1.93e-05	0.000329	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PPARG—type 2 diabetes mellitus	1.92e-05	0.000327	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TLE4—type 2 diabetes mellitus	1.9e-05	0.000325	CbGpPWpGaD
Vidarabine—ADK—Metabolism—INS—type 2 diabetes mellitus	1.88e-05	0.000321	CbGpPWpGaD
Vidarabine—ADA—Metabolism—APOB—type 2 diabetes mellitus	1.87e-05	0.000319	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—SRC—type 2 diabetes mellitus	1.86e-05	0.000317	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—GCG—type 2 diabetes mellitus	1.85e-05	0.000316	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ADRB3—type 2 diabetes mellitus	1.83e-05	0.000313	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—RASGRP1—type 2 diabetes mellitus	1.82e-05	0.000311	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GSTM1—type 2 diabetes mellitus	1.82e-05	0.00031	CbGpPWpGaD
Vidarabine—ADA—Metabolism—LPL—type 2 diabetes mellitus	1.79e-05	0.000305	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CRHR1—type 2 diabetes mellitus	1.77e-05	0.000302	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—GNB3—type 2 diabetes mellitus	1.76e-05	0.0003	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ADCY5—type 2 diabetes mellitus	1.75e-05	0.000298	CbGpPWpGaD
Vidarabine—ADA—Metabolism—GPX1—type 2 diabetes mellitus	1.74e-05	0.000297	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AVP—type 2 diabetes mellitus	1.73e-05	0.000296	CbGpPWpGaD
Vidarabine—ADK—Metabolism—ALB—type 2 diabetes mellitus	1.73e-05	0.000294	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CD36—type 2 diabetes mellitus	1.7e-05	0.00029	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PPP2CA—type 2 diabetes mellitus	1.68e-05	0.000286	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—IL6—type 2 diabetes mellitus	1.66e-05	0.000283	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3R1—type 2 diabetes mellitus	1.65e-05	0.000282	CbGpPWpGaD
Vidarabine—ADK—Metabolism—NOS3—type 2 diabetes mellitus	1.65e-05	0.000282	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—EDN1—type 2 diabetes mellitus	1.65e-05	0.000281	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PRKAA1—type 2 diabetes mellitus	1.63e-05	0.000279	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—EGFR—type 2 diabetes mellitus	1.63e-05	0.000277	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—IL6—type 2 diabetes mellitus	1.63e-05	0.000277	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SPRY2—type 2 diabetes mellitus	1.62e-05	0.000276	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MTNR1B—type 2 diabetes mellitus	1.62e-05	0.000276	CbGpPWpGaD
Vidarabine—ADA—Metabolism—MTHFR—type 2 diabetes mellitus	1.61e-05	0.000274	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—GNB3—type 2 diabetes mellitus	1.6e-05	0.000272	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PPARA—type 2 diabetes mellitus	1.58e-05	0.000269	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RBP4—type 2 diabetes mellitus	1.58e-05	0.000269	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GLP1R—type 2 diabetes mellitus	1.58e-05	0.000269	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AVP—type 2 diabetes mellitus	1.57e-05	0.000268	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—MMP3—type 2 diabetes mellitus	1.57e-05	0.000268	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—ADCY5—type 2 diabetes mellitus	1.57e-05	0.000267	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCKAR—type 2 diabetes mellitus	1.55e-05	0.000265	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AGT—type 2 diabetes mellitus	1.53e-05	0.000261	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTGS2—type 2 diabetes mellitus	1.51e-05	0.000257	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CALM1—type 2 diabetes mellitus	1.5e-05	0.000256	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—type 2 diabetes mellitus	1.5e-05	0.000256	CbGpPWpGaD
Vidarabine—ADA—Metabolism—APOE—type 2 diabetes mellitus	1.5e-05	0.000255	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EDN1—type 2 diabetes mellitus	1.5e-05	0.000255	CbGpPWpGaD
Vidarabine—ADA—Metabolism—APOA1—type 2 diabetes mellitus	1.48e-05	0.000253	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CCR5—type 2 diabetes mellitus	1.47e-05	0.000251	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—C3—type 2 diabetes mellitus	1.44e-05	0.000246	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—ADCY5—type 2 diabetes mellitus	1.42e-05	0.000243	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ATP2A2—type 2 diabetes mellitus	1.41e-05	0.00024	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IAPP—type 2 diabetes mellitus	1.4e-05	0.000238	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—INSR—type 2 diabetes mellitus	1.39e-05	0.000237	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AGT—type 2 diabetes mellitus	1.37e-05	0.000233	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TRPC6—type 2 diabetes mellitus	1.36e-05	0.000233	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PPP2CA—type 2 diabetes mellitus	1.36e-05	0.000232	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AGTR2—type 2 diabetes mellitus	1.36e-05	0.000231	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CCR5—type 2 diabetes mellitus	1.34e-05	0.000228	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—C3—type 2 diabetes mellitus	1.31e-05	0.000223	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PPARG—type 2 diabetes mellitus	1.3e-05	0.000222	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EDNRB—type 2 diabetes mellitus	1.3e-05	0.000222	CbGpPWpGaD
Vidarabine—ADA—Metabolism—INS—type 2 diabetes mellitus	1.28e-05	0.000218	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	1.26e-05	0.000216	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.26e-05	0.000215	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.26e-05	0.000215	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—IL6—type 2 diabetes mellitus	1.25e-05	0.000213	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AGT—type 2 diabetes mellitus	1.24e-05	0.000212	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.23e-05	0.000209	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.22e-05	0.000208	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.22e-05	0.000208	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.2e-05	0.000205	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.2e-05	0.000204	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.2e-05	0.000204	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.18e-05	0.000201	CbGpPWpGaD
Vidarabine—ADA—Metabolism—ALB—type 2 diabetes mellitus	1.17e-05	0.0002	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—AKT1—type 2 diabetes mellitus	1.15e-05	0.000197	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.15e-05	0.000196	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3R1—type 2 diabetes mellitus	1.12e-05	0.000191	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NOS3—type 2 diabetes mellitus	1.12e-05	0.000191	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.11e-05	0.00019	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.11e-05	0.000189	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GCG—type 2 diabetes mellitus	1.09e-05	0.000187	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.09e-05	0.000187	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.08e-05	0.000183	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.07e-05	0.000183	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTGS2—type 2 diabetes mellitus	1.03e-05	0.000175	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.02e-05	0.000175	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.01e-05	0.000171	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1e-05	0.000171	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	9.51e-06	0.000162	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	9.43e-06	0.000161	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AVP—type 2 diabetes mellitus	9.3e-06	0.000159	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	9.3e-06	0.000159	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	9.26e-06	0.000158	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	9.22e-06	0.000157	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	9.12e-06	0.000156	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	8.99e-06	0.000153	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	8.95e-06	0.000153	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	8.84e-06	0.000151	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	8.58e-06	0.000146	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.4e-06	0.000143	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.05e-06	0.000137	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	7.91e-06	0.000135	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—C3—type 2 diabetes mellitus	7.73e-06	0.000132	CbGpPWpGaD
Vidarabine—ADK—Metabolism—AKT1—type 2 diabetes mellitus	7.59e-06	0.000129	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.37e-06	0.000126	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.35e-06	0.000125	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	7.34e-06	0.000125	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.22e-06	0.000123	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	7.19e-06	0.000123	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	7.19e-06	0.000123	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.11e-06	0.000121	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.78e-06	0.000116	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.42e-06	0.000109	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—INS—type 2 diabetes mellitus	6.15e-06	0.000105	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.05e-06	0.000103	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.94e-06	0.000101	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.94e-06	0.000101	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.91e-06	0.000101	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.64e-06	9.63e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.39e-06	9.19e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.39e-06	9.19e-05	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AKT1—type 2 diabetes mellitus	5.16e-06	8.8e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	5.07e-06	8.65e-05	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.62e-06	7.88e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.58e-06	7.8e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.55e-06	7.75e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.32e-06	7.37e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.28e-06	7.3e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.19e-06	7.15e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	3.99e-06	6.8e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.88e-06	6.62e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.56e-06	6.08e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.49e-06	5.96e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.69e-06	4.58e-05	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.48e-06	4.22e-05	CbGpPWpGaD
